Meeting
2019 ASCO Annual Meeting
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
Authors
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal
Fatima Cardoso , Aditya Bardia , Fabrice Andre , David W. Cescon , Heather L. McArthur , Melinda L. Telli , Sherene Loi , Javier Cortes , Peter Schmid , Nadia Harbeck , Carsten Denkert , Christian Jackisch , Liyi Jia , Kim M. Hirshfield , Vassiliki Karantza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT03725059
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS601)
DOI
10.1200/JCO.2019.37.15_suppl.TPS601
Abstract #
TPS601
Poster Bd #
90b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2021 ASCO Annual Meeting
ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
First Author: Laurie Helen Sehn
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
First Author: Sherene Loi